This template was built with Webflow's free Prospero UI Kit. Learn more
If your child has an SCN2A diagnosis, you may have started hearing a new phrase in research updates: CRISPR activation, or CRISPRa. A landmark study published in Nature in late 2025 made headlines across the neuroscience world — and for good reason. For families navigating an SCN2A journey, understanding what this research means, and who it may one day help, is more important than ever.
This post breaks down CRISPRa in plain language: what it is, how it works, which mutation types it is designed for, and what the latest science shows. As always, this is educational information — not medical advice.
Most people have heard of CRISPR as a gene-editing tool — a molecular pair of scissors that can cut and change DNA. But CRISPRa is something different. Rather than cutting or editing a gene, CRISPRa turns a gene's volume up. It activates a gene that is already present, boosting its activity without making any permanent changes to the DNA sequence itself.
The technology uses a modified version of the Cas9 protein called dead Cas9 (dCas9) — "dead" because it cannot cut DNA. Instead, it is fused to a transcriptional activator: a molecular switch that tells the cell to produce more of a specific protein. A guide molecule called a single guide RNA (sgRNA) directs this complex to the right location on the genome — in this case, the promoter region of the SCN2A gene.
The result: the cell is prompted to make more of its own SCN2A protein using the copy of the gene it already has. No DNA is cut. No foreign gene is inserted. The body's own gene is simply encouraged to work harder.
To learn more about the SCN2A gene and how it affects the brain, visit our foundational overview.
The SCN2A gene encodes a protein called Nav1.2, a sodium channel that plays a critical role in how brain cells fire signals. When SCN2A function is insufficient, neurons cannot properly generate and transmit electrical signals — which affects learning, development, and in some children, seizure activity.
In SCN2A haploinsufficiency, a child has one functional copy of the SCN2A gene and one that does not produce a working protein. The healthy copy exists — it just is not producing enough Nav1.2 to compensate. This is precisely the scenario that CRISPRa was designed to address: find the healthy copy and dial it up to produce what the missing copy cannot.
Researchers at the University of California, San Francisco (UCSF) demonstrated in the 2025 Nature study that CRISPRa could do exactly this in both mouse models of SCN2A haploinsufficiency and in human stem-cell-derived neurons. The treated cells produced normal levels of Nav1.2 protein — and the neurons behaved accordingly, with restored signaling and improved connections.
This is one of the most important questions for families — and one of the most underreported aspects of this research. CRISPRa is not a therapy for all SCN2A mutations. Its applicability depends entirely on the type of mutation involved.
CRISPRa was specifically designed for loss-of-function (LOF) mutations — particularly those that cause haploinsufficiency. Haploinsufficiency means that one copy of the gene is non-functional and the remaining single copy cannot produce enough protein on its own to support typical brain function.
For children with complete LOF variants — where one copy of SCN2A produces no working protein at all — CRISPRa offers a compelling theoretical solution: boost the healthy copy to compensate for the silent one. Importantly, the researchers confirmed that a key prerequisite is that the variant allele must produce a non-functional transcript. CRISPRa activates both copies of the gene, so if the mutated copy is capable of being expressed at all, careful assessment is needed.
It is also important to note that this approach is best suited for variants that lead to a complete loss-of-function allele. Partial LOF variants or those with a residual functional transcript may require additional evaluation to determine suitability.
For children with gain-of-function (GOF) mutations, the picture is fundamentally different — and CRISPRa is not an appropriate approach. GOF mutations cause the Nav1.2 channel to be overactive, which is associated with neonatal-onset epilepsy and a distinct set of clinical features. Increasing SCN2A expression in a GOF context would risk amplifying that overactivity, potentially worsening outcomes.
The research team specifically tested whether CRISPRa could inadvertently cause harm by over-expressing SCN2A in healthy mice — and found that the brain appears to have a natural regulatory ceiling on Nav1.2 protein levels, which provides an important safety signal. Still, the researchers are clear: this modality targets LOF and haploinsufficiency, not GOF.
If you are unsure of your child's mutation type or classification, speaking with a geneticist or specialist in SCN2A disorders is an important first step. You can also explore the SCN2A research we're following for more context on how mutation type informs emerging therapies.
The landmark study published in Nature in December 2025 (Tamura et al.) was the culmination of years of work across multiple laboratories at UCSF and beyond. The researchers set out to answer a pivotal question: can CRISPRa rescue the neurological deficits caused by SCN2A haploinsufficiency — and can it do so even after early development has already occurred?
The answer was encouraging on both fronts. Working with mouse models designed to carry the same mutation type found in humans with SCN2A haploinsufficiency, the research team demonstrated the following:
One of the most significant findings was timing: the treatment worked in mice equivalent in developmental stage to children around 10 years old. This challenges the assumption that neurodevelopmental conditions caused by gene haploinsufficiency are only treatable in the earliest stages of life.
One practical challenge of any brain-targeting therapy is getting it where it needs to go. In the UCSF study, CRISPRa components were packaged into adeno-associated virus (AAV) vectors — small, naturally occurring viruses that have been engineered to carry therapeutic cargo into cells without causing disease. AAV vectors are already widely used in gene therapy research and several approved treatments.
The research team tested two delivery routes. Direct injection into the brain region of interest (stereotactic injection into the prefrontal cortex) produced clear results. But significantly, systemic delivery via the bloodstream was also effective — the AAV used in this study (PHP.eB) crosses the blood-brain barrier in certain mouse strains, reaching neurons throughout the brain after a tail vein injection.
The researchers acknowledge that the PHP.eB AAV serotype used here is effective in specific mouse strains but does not cross the blood-brain barrier as efficiently in humans or non-human primates. Future work will need to identify AAV variants or delivery strategies — such as focused ultrasound — that achieve comparable brain-wide distribution in humans.
For caregivers raising children with SCN2A LOF mutations, this research offers something deeply meaningful: scientific evidence that the biological underpinnings of their child's condition may be addressable — and potentially even at ages beyond early childhood.
It is important to hold this news with both hope and realistic expectations. This research is preclinical — meaning it has been conducted in mouse models and human cell cultures, not yet in human clinical trials. Several steps remain before any CRISPRa treatment could reach families, including long-term safety testing, optimization for human delivery systems, and regulatory review.
Regel Therapeutics, a biotechnology company that has licensed the UCSF CRISPRa technology, is actively working to translate this science toward clinical application. Their Targeted EpiEditing platform is designed to enable durable, cell-specific gene upregulation without altering the underlying DNA sequence.
The path from discovery to clinic is rarely short — but the foundation of evidence for CRISPRa in SCN2A haploinsufficiency is now meaningfully stronger than it was a year ago.
The 2025 Nature paper represents a proof-of-concept milestone — but the researchers and the wider SCN2A community understand that continued investment and scientific momentum are essential. Future steps in the CRISPRa research pipeline include:
The Foundation is actively monitoring this research and advocating for the resources needed to accelerate it. You can join the fight for SCN2A therapies and stay connected to the latest developments as they unfold.
Every family navigating an SCN2A diagnosis deserves answers, access to emerging research, and real hope for the future. There are two powerful ways to be part of the work that moves us forward. Sign up to stay connected and ensure your family is part of the network shaping what comes next. And if you are able, please consider making a donation to help fund the research and resources that bring us all closer to answers.
Medical Disclaimer: This content is provided for educational and informational purposes only and does not constitute medical advice. The information on this page is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
2. PubMed — CRISPR activation for SCN2A-related neurodevelopmental disorders
3. PMC Full Text — Tamura et al., 2025
4. UCSF News — Can CRISPR Fix a Childhood Brain Disorder? September 16, 2025
5. SFARI — Development of CRISPR Activation Therapeutics to Rescue SCN2A Function
6. Regel Therapeutics Press Release — Landmark UCSF Study. September 17, 2025
Share
If your child has an SCN2A diagnosis, you may have started hearing a new phrase in research updates: CRISPR activation, or CRISPRa. A landmark study published in Nature in late 2025 made headlines across the neuroscience world — and for good reason. For families navigating an SCN2A journey, understanding what this research means, and who it may one day help, is more important than ever.
This post breaks down CRISPRa in plain language: what it is, how it works, which mutation types it is designed for, and what the latest science shows. As always, this is educational information — not medical advice.
Most people have heard of CRISPR as a gene-editing tool — a molecular pair of scissors that can cut and change DNA. But CRISPRa is something different. Rather than cutting or editing a gene, CRISPRa turns a gene's volume up. It activates a gene that is already present, boosting its activity without making any permanent changes to the DNA sequence itself.
The technology uses a modified version of the Cas9 protein called dead Cas9 (dCas9) — "dead" because it cannot cut DNA. Instead, it is fused to a transcriptional activator: a molecular switch that tells the cell to produce more of a specific protein. A guide molecule called a single guide RNA (sgRNA) directs this complex to the right location on the genome — in this case, the promoter region of the SCN2A gene.
The result: the cell is prompted to make more of its own SCN2A protein using the copy of the gene it already has. No DNA is cut. No foreign gene is inserted. The body's own gene is simply encouraged to work harder.
To learn more about the SCN2A gene and how it affects the brain, visit our foundational overview.
The SCN2A gene encodes a protein called Nav1.2, a sodium channel that plays a critical role in how brain cells fire signals. When SCN2A function is insufficient, neurons cannot properly generate and transmit electrical signals — which affects learning, development, and in some children, seizure activity.
In SCN2A haploinsufficiency, a child has one functional copy of the SCN2A gene and one that does not produce a working protein. The healthy copy exists — it just is not producing enough Nav1.2 to compensate. This is precisely the scenario that CRISPRa was designed to address: find the healthy copy and dial it up to produce what the missing copy cannot.
Researchers at the University of California, San Francisco (UCSF) demonstrated in the 2025 Nature study that CRISPRa could do exactly this in both mouse models of SCN2A haploinsufficiency and in human stem-cell-derived neurons. The treated cells produced normal levels of Nav1.2 protein — and the neurons behaved accordingly, with restored signaling and improved connections.
This is one of the most important questions for families — and one of the most underreported aspects of this research. CRISPRa is not a therapy for all SCN2A mutations. Its applicability depends entirely on the type of mutation involved.
CRISPRa was specifically designed for loss-of-function (LOF) mutations — particularly those that cause haploinsufficiency. Haploinsufficiency means that one copy of the gene is non-functional and the remaining single copy cannot produce enough protein on its own to support typical brain function.
For children with complete LOF variants — where one copy of SCN2A produces no working protein at all — CRISPRa offers a compelling theoretical solution: boost the healthy copy to compensate for the silent one. Importantly, the researchers confirmed that a key prerequisite is that the variant allele must produce a non-functional transcript. CRISPRa activates both copies of the gene, so if the mutated copy is capable of being expressed at all, careful assessment is needed.
It is also important to note that this approach is best suited for variants that lead to a complete loss-of-function allele. Partial LOF variants or those with a residual functional transcript may require additional evaluation to determine suitability.
For children with gain-of-function (GOF) mutations, the picture is fundamentally different — and CRISPRa is not an appropriate approach. GOF mutations cause the Nav1.2 channel to be overactive, which is associated with neonatal-onset epilepsy and a distinct set of clinical features. Increasing SCN2A expression in a GOF context would risk amplifying that overactivity, potentially worsening outcomes.
The research team specifically tested whether CRISPRa could inadvertently cause harm by over-expressing SCN2A in healthy mice — and found that the brain appears to have a natural regulatory ceiling on Nav1.2 protein levels, which provides an important safety signal. Still, the researchers are clear: this modality targets LOF and haploinsufficiency, not GOF.
If you are unsure of your child's mutation type or classification, speaking with a geneticist or specialist in SCN2A disorders is an important first step. You can also explore the SCN2A research we're following for more context on how mutation type informs emerging therapies.
The landmark study published in Nature in December 2025 (Tamura et al.) was the culmination of years of work across multiple laboratories at UCSF and beyond. The researchers set out to answer a pivotal question: can CRISPRa rescue the neurological deficits caused by SCN2A haploinsufficiency — and can it do so even after early development has already occurred?
The answer was encouraging on both fronts. Working with mouse models designed to carry the same mutation type found in humans with SCN2A haploinsufficiency, the research team demonstrated the following:
One of the most significant findings was timing: the treatment worked in mice equivalent in developmental stage to children around 10 years old. This challenges the assumption that neurodevelopmental conditions caused by gene haploinsufficiency are only treatable in the earliest stages of life.
One practical challenge of any brain-targeting therapy is getting it where it needs to go. In the UCSF study, CRISPRa components were packaged into adeno-associated virus (AAV) vectors — small, naturally occurring viruses that have been engineered to carry therapeutic cargo into cells without causing disease. AAV vectors are already widely used in gene therapy research and several approved treatments.
The research team tested two delivery routes. Direct injection into the brain region of interest (stereotactic injection into the prefrontal cortex) produced clear results. But significantly, systemic delivery via the bloodstream was also effective — the AAV used in this study (PHP.eB) crosses the blood-brain barrier in certain mouse strains, reaching neurons throughout the brain after a tail vein injection.
The researchers acknowledge that the PHP.eB AAV serotype used here is effective in specific mouse strains but does not cross the blood-brain barrier as efficiently in humans or non-human primates. Future work will need to identify AAV variants or delivery strategies — such as focused ultrasound — that achieve comparable brain-wide distribution in humans.
For caregivers raising children with SCN2A LOF mutations, this research offers something deeply meaningful: scientific evidence that the biological underpinnings of their child's condition may be addressable — and potentially even at ages beyond early childhood.
It is important to hold this news with both hope and realistic expectations. This research is preclinical — meaning it has been conducted in mouse models and human cell cultures, not yet in human clinical trials. Several steps remain before any CRISPRa treatment could reach families, including long-term safety testing, optimization for human delivery systems, and regulatory review.
Regel Therapeutics, a biotechnology company that has licensed the UCSF CRISPRa technology, is actively working to translate this science toward clinical application. Their Targeted EpiEditing platform is designed to enable durable, cell-specific gene upregulation without altering the underlying DNA sequence.
The path from discovery to clinic is rarely short — but the foundation of evidence for CRISPRa in SCN2A haploinsufficiency is now meaningfully stronger than it was a year ago.
The 2025 Nature paper represents a proof-of-concept milestone — but the researchers and the wider SCN2A community understand that continued investment and scientific momentum are essential. Future steps in the CRISPRa research pipeline include:
The Foundation is actively monitoring this research and advocating for the resources needed to accelerate it. You can join the fight for SCN2A therapies and stay connected to the latest developments as they unfold.
Every family navigating an SCN2A diagnosis deserves answers, access to emerging research, and real hope for the future. There are two powerful ways to be part of the work that moves us forward. Sign up to stay connected and ensure your family is part of the network shaping what comes next. And if you are able, please consider making a donation to help fund the research and resources that bring us all closer to answers.
Medical Disclaimer: This content is provided for educational and informational purposes only and does not constitute medical advice. The information on this page is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
2. PubMed — CRISPR activation for SCN2A-related neurodevelopmental disorders
3. PMC Full Text — Tamura et al., 2025
4. UCSF News — Can CRISPR Fix a Childhood Brain Disorder? September 16, 2025
5. SFARI — Development of CRISPR Activation Therapeutics to Rescue SCN2A Function
6. Regel Therapeutics Press Release — Landmark UCSF Study. September 17, 2025
Vlad Magdalin
